FRN-HM101-100μg / 询价
FRN-HM101-500μg / 询价
FRN-HM101-500μgx2 / 询价
Human FcRn Protein
Recombinant Human FcRn Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Ala24-Ser297(FCGRT) & Ile21-Met119(B2M) [Accession | P55899-1(FCGRT)&P61769-1(B2M)].
The protein has a predicted MW of 31.5 kDa (FCGRT)&11.7 kDa (B2M). Due to glycosylation, the protein migrates to 35-40 kDa (FCGRT)&13-14 kDa (B2M) based on Bis-Tris PAGE result.
>95% as determined by Bis-Tris PAGE
>95% as determined by HPLC
Less than 1 EU per ug by the LAL method.
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human FcRn on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human FcRn is greater than 95% as determined by SEC-HPLC.
Immobilized Human FcRn, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-FcRn Antibody, hFc Tag with the EC50 of 5.4 ng/ml determined by ELISA (QC Test).
Human FcRn, His Tag captured on CM5 Chip via anti-his antibody can bind Human IgG1 Fc, No Tag with an affinity constant of 0.28 μM as determined in SPR assay (Biacore T200).
The neonatal Fc receptor (FCRN) is an approximately 45 kDa transmembrane glycoprotein with structural homology to MHC class I proteins. It is widely expressed in endothelial and epithelial cells and plays an important role in IgG homeostasis and antigen presentation by dendritic cells.FCGRT&B2M heterodimer protein (FcRn complex) consist of two subunits: p51, and p14 , and forms an MHC class I-like heterodimer.
FcRn alpha chain; FCGRT; FCRN; FCGRT&B2M
(1) Kiessling P , Lledo-Garcia R , Watanabe S , et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study[J]. Science translational medicine, 2017, 9(414):eaan1208.
